GLP-1 drugs and mental health: what the data says about anxiety

What did @cococolaah actually say?

She said semaglutide has not personally worsened her anxiety, and she thinks the low dose may be a factor. She was upfront: this is one person's experience, she consulted her doctor first, and she has depression, ADHD, and situational anxiety. She said, "it has not spiked personally like my own anxiety" and credited staying on "a small dose" as potentially relevant. She explicitly told viewers to consult their own doctor. That framing matters. This is not someone claiming a treatment is safe for everyone. It is someone answering a direct question about their own body. Give credit where it is due: this is how anecdotal health content should be shared.

Does the science back this up?

The honest answer is: it is complicated, and the data is genuinely mixed. GLP-1 receptor agonists do not have a clean anxiety signal in clinical trials, but that does not mean no signal exists. The FDA label for semaglutide (Wegovy, Ozempic) does not list anxiety as a common adverse event. However, post-marketing surveillance and real-world reports have flagged mood-related concerns enough that the FDA added a warning to monitor for psychiatric symptoms. A 2023 pharmacovigilance analysis in Diabetes, Obesity and Metabolism (Gao et al.) found no statistically significant increase in anxiety-related adverse events for GLP-1 agonists compared to other diabetes medications. Separately, some researchers have argued GLP-1 receptors in the brain may actually have anxiolytic properties in animal models, though human data is not conclusive. The "low dose reduces side effects" claim has plausible biological support, since dose-dependent GI and autonomic effects are well-documented.

What did they get wrong (or right)?

She got the framing right. She got the dose-dependency point roughly right. What is missing, though not wrong, is that anxiety is a documented withdrawal-adjacent symptom for some users during dose escalation, not just at stable doses. The transition between doses is where some users report increased irritability and anxiety, likely tied to GI stress and sleep disruption rather than direct neurological action. She also does not mention that people with pre-existing mood disorders, including depression and ADHD (her own diagnoses), may respond differently than people without those conditions. Some small studies suggest GLP-1 agonists may modestly improve depressive symptoms, possibly through inflammation reduction or weight-related quality of life improvements. That would be consistent with her not noticing worsening. But it is not universal, and the evidence is early.

What should you actually know?

If you have a pre-existing anxiety disorder and are considering a GLP-1 medication, here is what is actually known. First, anxiety is not listed as a common side effect in phase 3 trials for semaglutide. Second, the FDA does flag that suicidal ideation and psychiatric events should be monitored, which is not the same as saying the drug causes them, but it does mean this should be part of an informed conversation with your prescriber. Third, dose and titration speed genuinely matter for tolerability. Fourth, individual variability is real. Two people with the same diagnoses can have completely different experiences. Fifth, one TikTok video, however well-intentioned, cannot substitute for a conversation with a provider who knows your full psychiatric and medication history. She said that herself, and she is right.